James Sandy, formerly of Creabilis Ltd, has joined UK-based Immunocore Ltd as the company’s chief development officer where he will lead clinical development of the company’s immuno-oncology drugs known as ImmTACs. Prior to working for Creabilis, Mr Sandy held a number of senior positions at Pfizer Inc including head of European and Asian development operations.
Separately, Immunocore has appointed Julian Hirst as director of corporate finance. Mr Hirst joined the company as a consultant in early 2015 and has been promoted. He was previously head of corporate finance at Panmure Gordon.
Immunocore announced the appointments on 17 December 2015.
Copyright 2015 Evernow Publishing Ltd